Close Menu

NEW YORK – Astellas Pharma said on Thursday that its new drug application for gilteritinib (Astellas' Xospata) was accepted by China's National Medical Products Administration for regulatory review.

Gilteritinib is intended to treat relapsed or refractory acute myeloid leukemia patients who harbor a FLT3 mutation, a common oncogenic driver of the disease. The drug was approved in 2018 for this setting in the US alongside Invivoscribe Technologies' LeukoStrat CDx companion diagnostic for identifying FLT3 mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.